Sanofi scraps Phase 3 trial after riliprubart fails in CIDP patients

Sanofi scraps Phase 3 trial after riliprubart fails in CIDP patients

Sanofi's $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble

Sanofi scraps Phase 3 trial after riliprubart fails in CIDP patients

Sanofi has halted a major Phase 3 study for its drug riliprubart after it failed to show effectiveness. The decision marks a setback for the company following its $11.6bn acquisition of Bioverativ in 2018. The acquisition had previously delivered successes like Altuviiio, a haemophilia A treatment approved in 2023. The MOBILIZE study tested riliprubart in 140 patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). It ran across 134 sites worldwide. An interim analysis found the C1s inhibitor drug did not meet its goals, prompting Sanofi to abandon the trial.

The company is now reviewing other ongoing studies of riliprubart. The setback raises questions about the long-term value of the Bioverativ deal. While Altuviiio has become a blockbuster, with Q1 2026 sales of around €325 million, another C1s inhibitor from the same acquisition, Enjaymo, was sold to Recordati for $825 million in 2022. Sanofi’s decision to stop the MOBILIZE study ends its efforts with riliprubart in CIDP. The company will reassess its remaining research on the drug. Despite Altuviiio’s strong performance, the failure of riliprubart adds uncertainty to the Bioverativ acquisition’s overall success.

Neueste Nachrichten